A system validated in year one is less likely to behave the same way three years and several software patches later. That difference, between what was signed off once and what an IT environment does today, now accounts for a growing share of pharma IT compliance findings.
It’s nothing to do with policy. Most global pharmaceutical organizations can produce a validation plan and a stack of current SOPs within a day of being asked. Regulators are now testing whether the environment behind those documents still works the way the documents describe, at the site where the product is made, this year, not only at the point the system was first qualified.
Part of the reason that’s harder to prove than it used to be is that pharma’s manufacturing footprint now extends well beyond a company’s own walls. Outsourced manufacturing covers roughly 40% of global pharmaceutical production, up from about 30% in 2018, according to a 2026 market analysis from . Each contract site runs on its own patch schedule, often reviewed by a quality team several time zones from headquarters. That adds one more version of how things run day to day – and one more version that has to match what’s on file.
Beyond Policy and Frameworks
Pull a handful of recent regulatory findings, and a familiar shape turns up. A validated system running two patch versions behind at one site, compared with another in the same network. An access review that happens like clockwork at headquarters and only sporadically at a facility that opened eighteen months ago. Both hold the same SOP on file, though only one of them still matches it in practice.
Findings like these get logged as quality events, though the cause usually traces to how the IT function delivers and maintains the environment day to day.
The FDA’s own recent guidance points in a similar direction. Its finalized Computer Software Assurance guidance, written for device production and quality-system software, treats native digital records, such as system logs and audit trails, as stronger assurance evidence than paper printouts assembled after the fact. That guidance covers a narrow slice of regulated software. But the principle behind it – digital evidence in place of paperwork assembled after the fact – is one that pharma quality and IT leaders now recognize well beyond device manufacturing.
From Point-in-Time to Always-On
Pharmaceutical manufacturing already went through this shift, just not for IT yet. The FDA’s 2011 process validation guidance replaced the old three-batch model with a lifecycle that ends in what it calls Continued Process Verification: ongoing evidence, collected throughout commercial production, that a process stays in a state of control, with no final sign-off stage.
Computerized systems have mostly avoided that shift. The habit is to validate once, then leave the system alone until a change request reopens the file. That held up well enough when systems changed rarely and each site ran independently. A single manufacturing network spanning a company’s own sites and a growing list of contract manufacturers, each on its own patch cycle and access model, is a different problem entirely.
Applying that same logic to pharma IT operations changes daily practice in a few ways. Validation becomes ongoing rather than a project with an end date. Systems get monitored for who’s accessing them and what’s changing inside them, continuously, not reconstructed afterward from logs nobody checked in real time. The same standard holds at every site and with every vendor, instead of drifting according to whoever happens to be managing it locally. IT teams start reviewing that evidence alongside compliance teams, so neither is caught off guard by what the other finds. Better documentation can’t deliver any of that by itself; it takes an operating model built to sustain it.
How Maintech Supports Global Pharma Operations
Reducing this exposure starts with treating IT delivery as something to standardize, not improvise site by site. One operating model, held consistently across every location where a company manufactures or holds regulated data, closes off the most common source of a finding – the local exception nobody wrote down.
Maintech works with global pharmaceutical and life sciences organizations on this exact problem, building standardized IT environments held to one specification across every site, instead of one specification on paper and several versions in practice. That includes keeping access control and audit trails running and reviewed continuously, the kind of ongoing evidence regulators now expect, rather than something assembled the week before an inspection. In one recent engagement, Maintech supported the security and disaster-recovery posture of a pharmaceutical SaaS platform, testing recovery processes and keeping the underlying infrastructure patched and monitored on an ongoing basis.
Where a company’s own sites operate alongside a growing base of contract manufacturers, that consistency needs one accountable partner behind it, not a separate negotiation with each vendor. Built on directly employed, in-country technical staff instead of layers of subcontracted labor, that model scales alongside a growing manufacturing network without reintroducing the kind of site-by-site drift GxP environments are least able to absorb.
How consistently IT environments are delivered and maintained across the organization is now central to a pharma company’s regulatory risk, standing alongside the compliance frameworks written to manage it.
Speak with a Maintech expert to assess how your IT delivery model supports compliance and continuity.
